PubRank

Dana J H Niehaus

Author PubWeight™ 30.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008 1.25
2 Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004 1.08
3 Perceptions of a South African schizophrenia population with regards to community attitudes towards their illness. Soc Psychiatry Psychiatr Epidemiol 2006 1.07
4 Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008 1.05
5 Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008 1.04
6 Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry 2005 1.03
7 Childhood trauma in obsessive-compulsive disorder, trichotillomania, and controls. Depress Anxiety 2002 1.01
8 Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. J Clin Psychiatry 2005 1.01
9 Trichotillomania and skin-picking: a phenomenological comparison. Depress Anxiety 2002 1.01
10 Obsessive-compulsive disorder and trichotillomania: a phenomenological comparison. BMC Psychiatry 2005 0.99
11 Deficits in facial affect recognition in unaffected siblings of Xhosa schizophrenia patients: evidence for a neurocognitive endophenotype. Schizophr Res 2007 0.96
12 Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 2010 0.91
13 Early- versus late-onset obsessive-compulsive disorder: investigating genetic and clinical correlates. Psychiatry Res 2004 0.90
14 Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010 0.90
15 Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006 0.89
16 Dissociative experiences in obsessive-compulsive disorder and trichotillomania: clinical and genetic findings. Compr Psychiatry 2004 0.88
17 Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenet Genomics 2013 0.88
18 Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002 0.87
19 Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 2012 0.87
20 Gender in obsessive-compulsive disorder: clinical and genetic findings. Eur Neuropsychopharmacol 2004 0.86
21 Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 2011 0.86
22 The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 2006 0.84
23 Negative symptoms and HIV/AIDS risk-behavior knowledge in schizophrenia. Psychosomatics 2007 0.81
24 Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. Eur Neuropsychopharmacol 2003 0.81
25 Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry 2007 0.81
26 Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics 2014 0.80
27 Corrigendum to "gender in obsessive-compulsive disorder: clinical and genetic findings" [Eur. Neuropsychopharmacol. 14 (2004) 105-113]. Eur Neuropsychopharmacol 2004 0.79
28 Allocation of attention to the eye and mouth region of faces in schizophrenia patients. Cogn Neuropsychiatry 2008 0.78
29 Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol 2006 0.78
30 Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2008 0.78
31 Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res 2008 0.78
32 Morphological features in a Xhosa schizophrenia population. BMC Psychiatry 2006 0.77
33 Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Prog Neuropsychopharmacol Biol Psychiatry 2012 0.76
34 Season of birth, age and negative symptoms in a Xhosa schizophrenia sample from the Southern Hemisphere. Aust N Z J Psychiatry 2006 0.76
35 Facial affect recognition and exit examination performance in medical students: a prospective exploratory study. BMC Med Educ 2014 0.75
36 The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. Pharmacogenet Genomics 2016 0.75
37 Prevalence of obsessive compulsive disorder in first- and multi-episode male patients with schizophrenia-spectrum disorders. S Afr Med J 2003 0.75
38 Chromosome 22q11 in a Xhosa schizophrenia population. S Afr Med J 2012 0.75